People: Medibio Ltd (BPO.AX)

BPO.AX on Australia Stock Exchange

0.00AUD
24 Nov 2014
Price Change (% chg)

-- (--)
Prev Close
$0.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,472,278
52-wk High
$0.00
52-wk Low
$0.00

Search Stocks

Summary

Name Age Since Current Position

Vincent Fayad

2014 Non-Executive Chairman of the Board

Robert Lees

2012 Chief Financial Officer, Company Secretary

Kris Knauer

2014 Executive Director

Biographies

Name Description

Vincent Fayad

Mr. Vince John Paul Fayad has been appointed as Non-Executive Chairman of the Board of BioProspect Limited., with effect from 29 April 2014. Mr Fayad is currently a Director of PKF Lawler Corporate Finance, specialising in the area of corporate finance and business consulting. Mr. Fayad has had over 30 years of professional services advisory and account ing experience, particularly with listed companies. He has advised several listed companies, including biotechnology companies, on strategic areas of business growth , corporate governance and merger and acquisitions, including funding and capital raising. Mr. Fayad is currently a non- executive Director of Esperance Minerals.

Robert Lees

Mr. Robert (Rob) Edward Lees has been Chief Financial Officer and Company Secretary of BioProspect Ltd since September 28, 2012. He is member of the Institute of Chartered Accountants in Australia and Chartered Secretaries of Australia. He is a graduate of the University of Technology Sydney, holding a Bachelor of Business (Accounting) and a Graduate Diploma in Data Processing. He also holds a Graduate Diploma in Corporate Governance. Mr. Lees qualified as a Chartered Accountant with KPMG (Sydney) in the Audit Division. He has worked in private practice, small business advice, venture capital (BT Innovation Ltd) and as a Financial Controller/Company Secretary of a number of medium sized enterprises, including in a division of an ASX listed company, Email Limited. In the last 12 years, Mr. Lees has provided Company Secretarial and Chief Financial officer (CFO) services to several ASX listed companies. This has included working on 10 IPO’s and back door listings. He was Company Secretary for Citadel Resource Group Limited from Nov 2003 to Feb 2009 and Norton Gold Fields Limited from December 2004 to February 2007. He is currently Company Secretary of five ASX listed companies and one NSX listed company.

Kris Knauer

Mr. Kris David Knauer ha been appointed as Executive Director of BioProspect Ltd., with effect from 2 July 2014. Kris has a wealth of experience particularly in ASX Listed companies and is also a key shareholder and convertible noteholder of the Company. Kris has been a consultant to the Company and has been actively involved in the due diligence process and subsequently in providing corporate and strategic advice to BioProspect. Kris’ will focus corporate matters such as the Board and Senior Management composition and structure, Capital structure, and the ongoing funding requirements for commercialisation of Invatec’s HRV technology for the diagnosis of Depression and other Mental Health conditions. Kris has a Bachelor of Science (Honours). Mr Knauer also has over 15 years’ experience in finance and corporate advisory services. He is currently Executive Director Equities at Novus Capital Limited with a key focus on smaller listed companies. Mr Knauer is currently the Executive Chairman of Esperance Minerals Limited (ASX: ESM), Non-Executive Chairman of Astro Resources NL (ASX: ARO), Non-Executive Director of Greenvale Mining NL (ASX: GRV) and a former director of Citadel Resource Group Limited (ASX: CGG).

Basic Compensation

Name Fiscal Year Total

Vincent Fayad

--

Robert Lees

53,279

Kris Knauer

--
As Of 29 Jun 2013

Options Compensation

Name Options Value

Vincent Fayad

0 0

Robert Lees

0 0

Kris Knauer

0 0
Search Stocks